Chapel Hill CRS – ACTG Network

Location	UNC Hospitals – CTRC Bioinformatics Building 2nd Floor Suite 2100 130 Mason Farm Road Chapel Hill NC 27599-7215
CRS Coordinator	Erin Elizabeth Hoffman erin_hoffman@med.unc.edu 919-843-0720 Chapel Hill CRS (3201) 2100 Bioinformatics Building 130 Mason Farm Road, CB#7215 Chapel Hill, NC 27599-7215 United States of America
CRS Leader	David Wohl wohl@med.unc.edu 919-843-2723 Chapel Hill CRS Suite 2100, Bioinformatics Building 130 Mason Farm Road Chapel Hill, NC 27514 United States of America
Studies	A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5332: REPRIEVE Trial A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) ACTG A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)